Preparation method of spirostane type steroid alkaloid and application of spirostane type steroid alkaloid in resisting enteritis
By preparing and identifying propanediol solaoiate, the drug resistance and adverse reaction problems in existing IBD treatment methods were solved, which significantly alleviated the symptoms of ulcerative colitis and was a novel anti-ulcerative colitis. Drug development provides guidance.
Patent Information
- Application Number
- CN202411268917.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-11
- Publication Date
- 2024-12-06
AI Technical Summary
Existing treatments for inflammatory bowel disease (IBD) are resistant to drug and severe adverse reactions, and lack safe and efficient anti-inflammatory drugs.
Fresh sunflower juice was isolated and purified by ODS reverse phase column and gel column, and the spirosteroid steroid alkaloid propanediol solaoiate was identified and prepared, and its anti-inflammatory activity was verified in vitro and in vivo experiments to relieve ulcerative colitis. .
The structure and preparation method of propanediol solaoiate were reported for the first time, which significantly improved the survival status of mice with ulcerative colitis, alleviated the shortening of colon length and intestinal necrosis bleeding, and downregulated serum The content of proinflammatory factors IL-1β and TNF-α provides new approaches to treat enteritis and drug screening guidance.
Smart Images

Figure CN119080866A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine and discloses a preparation method of a spirostane-type steroidal alkaloid and an application thereof in preventing enteritis. Background Art
[0002] Inflammatory bowel disease (IBD) is a nonspecific, chronic, recurrent, inflammatory disease that mainly affects the gastrointestinal tract. The main symptoms are abdominal pain and cramps, rectal pain, and rectal bleeding. Serious complications such as toxic megacolon, intestinal perforation, severe dehydration, and cancer may occur. IBD mainly includes ulcerative colitis (UC) and Crohn's disease (CD). The incidence of IBD has stabilized in Western countries, but is in a rapid growth stage in emerging industrialized countries. Studies have shown that changes in genetic genes, environment, immune system, and intestinal flora are the main factors leading to the development of IBD. At present, the main treatment for IBD is drug therapy, including antibiotics, immunomodulators, aminosalicylate, glucocorticoids, biological agents, etc., but long-term use is very likely to produce drug resistance and serious adverse reactions, including hepatotoxicity, bone marrow toxicity, nephrotoxicity, osteonecrosis, cataracts, diabetes, hypertension, etc. At present, a combination of Chinese and Western medicine has been developed in China. Western medicine aims to quickly control the development of the disease, while Chinese medicine focuses on subsequent consolidation. Natural products not only have good anti-inflammatory effects, but also have the advantages of high safety and few side effects.
[0003] Spirosalane alkaloids are widely found in Solanaceae plants, mainly including solasodine, tomatidine, and tomatidenol. Spirosalane alkaloids have been reported to exhibit strong anti-tumor and anti-inflammatory activities in vitro and in vivo experiments, and can reduce the content of pro-inflammatory cytokines such as IL-1β and IL-6 in inflammatory models and inhibit the production of NO. Previous studies have shown that fresh Solanum nigrum juice can relieve the symptoms of ulcerative colitis, and its main component is spirostane alkaloids, but the structure of some of its compounds and anti-enteritis activity have not been reported. Summary of the invention
[0004] The purpose of the present invention is to clarify the preparation method of a spirostane steroidal alkaloid and its application in anti-enteritis, and to provide a potential safe drug for inflammatory response.
[0005] In order to achieve the above object, the present invention adopts the following technical scheme:
[0006] A preparation method of spirostane steroidal alkaloids and their application in anti-enteritis.
[0007] The principles and advantages of this technical solution are:
[0008] The inventors conducted a large number of experiments to verify and explore the preparation method and anti-enteritis application of spirostane steroidal alkaloid propanediolsolaoiate, as follows:
[0009] (1) Preparation method of spirostane steroidal alkaloid propanediol solaoiate: fresh Solanum nigrum juice was separated and purified by ODS reverse phase column and gel column, and the results were analyzed by color reaction, high resolution mass spectrometry, 1 H NMR, 13 C NMR confirmed that the obtained compound was a spirostane steroidal alkaloid.
[0010] (2) Structural identification of a spirostane steroidal alkaloid propanediol solaoiate: by colorimetric reaction, mass spectrometry, 1 H NMR, 13 C NMR, HSQC, HMBC, 1 H- 1 H COSY and ROESY were used to identify the structures of spirostane steroidal alkaloids.
[0011] (3) Evaluation of the in vitro anti-inflammatory activity of a spirostane steroidal alkaloid propanediol solaoiate: LPS / IFN-γ was used to induce polarization of macrophages RAW264.7, and the effects of this spirostane steroidal alkaloid on the secretion of ROS and IL-1β in macrophages were detected using a DCFH-DA probe and an ELISA kit.
[0012] (4) Effects of propanediol solaoiate, a spirostane steroidal alkaloid, on DSS-induced IBD model mice: First, the weight changes and survival of mice were counted. Second, the colon length, spleen index, and colon tissue morphology of each group of mice were compared. Finally, the levels of inflammatory factors in the serum of each group of mice were detected.
[0013] Compared with the prior art, this technical solution has the following beneficial effects.
[0014] The present invention reports for the first time the structure and preparation method of a spirostane steroidal biological propanediol solaoiate. In addition, the present invention reports for the first time that this spirostane steroidal alkaloid can improve the survival state of mice with ulcerative colitis constructed by sodium dextran sulfate, alleviate the shortening of colon length and intestinal necrosis and bleeding, and reduce the content of pro-inflammatory factors IL-1β and TNF-α in serum. The above findings can provide a therapeutic drug for enteritis, providing new ideas for further research on the pathogenesis of ulcerative colitis; at the same time, this spirostane steroidal alkaloid propanediol solaoiate can be used in the screening and testing of new anti-ulcerative colitis drugs, providing guidance for the development of new drugs for the treatment of enteritis. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is the chemical structural formula of the spirostane steroidal alkaloid propanediol solaoiate in Example 1; Figure 2 The mass spectrum, hydrogen spectrum and carbon spectrum of the spirostane steroidal alkaloid propanediol solaoiate in Example 1; Figure 3 The HSQC spectrum and key HMBC, 1 H- 1 H COSY related; Figure 4 The ROESY spectrum and key related peaks of the spirostane steroidal alkaloid propanediol solaoiate in Example 2; Figure 5 The images and statistical graphs of DCFH-DA fluorescent probe incubated in macrophage RAW264.7 of the blank group, model group and propanediol solaoiate administration group in Example 3, as well as the statistical graphs of inflammatory factors; Figure 6 The graphs are the body weight change curves and survival time curves of the blank group, model group and propanediol solaoiate administration group mice in Example 4; Figure 7 The colon pictures, colon length statistics, and spleen index statistics of the mice in the blank group, model group, and propanediol solaoiate administration group in Example 4; Figure 8 The colon tissue H&E staining and pathological tissue scoring statistical results of the blank group, model group and propanediol solaoiate administration group mice in Example 4; Fig. 9This is a statistical chart of serum pro-inflammatory cytokines in the blank group, model group and propanediol solaoiate administration group of mice in Example 4. DETAILED DESCRIPTION
[0015] In order to better illustrate the purpose, technical scheme and advantages of the present invention, the present invention will be further described below in conjunction with the accompanying drawings and specific embodiments. In the following examples, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all commercially available unless otherwise specified.
[0016] Example 1: A method for preparing spirostane-type steroidal alkaloids
[0017] 1 Experimental methods
[0018] Fresh ripe Solanum nigrum fruit was ground at 4°C, centrifuged at 13000g for 10 min, and the supernatant was added to an ODS-AQ-HG reverse phase column. The column was gradient eluted with acetonitrile and 0.1% formic acid water (10% to 15%) to obtain 79 fractions. Fraction 3-1 was further purified on an HW-40F gel column and eluted with water to obtain 42 fractions. Each fraction was detected by TLC using a developing system of n-butanol-glacial acetic acid-water (4:1:5, upper layer), and one compound was obtained from 3-1-7 to 3-1-9. 5 mg of the compound was dissolved in deuterated methanol and obtained using a 500MHZ nuclear magnetic resonance spectrometer. 1 HNMR, 13 C NMR spectrum analysis
[0019] 2 Experimental results
[0020] As the instruction manual Figure 2 As shown in (A), the quasi-molecular ion peak of the compound [M+H] + m / z is 988.5022. Figure 2 (B) 1 H NMR spectrum showed δ H 0.82(3H,s,Me-18),δ H 1.07(3H,s,Me-19),δ H 1.19(3H,d,J=6.16HZ,Me-21), δ H 1.19(3H,d,J=6.16HZ,Me-29), δ H 1.24 (3H, d, J = 6.11HZ, Rha-6) is the methyl signal peak. H 5.40 (1H, d, J = 3.29HZ, H-6) is the hydrogen signal on the unsaturated double bond. Figure 2 (C) 13 C NMR spectrum showed δ c171.35 (C-27) is the carboxyl ester carbon signal, δ c 141.95(C-5) and δ c 122.53 (C-6) is the unsaturated double bond carbon signal, δ c 103.12 (C-22) is the carbon signal connected to the nitrogen atom, which is the characteristic carbon signal of spirostane alkaloids. c 100.50(Gal-1),δ c 102.36 (Rha-1), δ c 102.50 (Man-1) shows three sugar terminal carbon signals. The above results show that the compound is a spirostane-type steroidal alkaloid containing trisaccharides. H 4.50(1H,d,J=7.92HZ),δ H 4.88 (1H, d, J = 1.52HZ) are the hydrogen signals of H-Gal-1 and H-Man-1, respectively. Based on their coupling constants, it can be determined that galactose is in β configuration and mannose is in α configuration. c 72.39), C-Rha-5(δ c The chemical shift value of 69.76) can confirm that rhamnose is in the α configuration.
[0021] Example 2: Structural Identification of a Spirostane-type Steroidal Alkaloid
[0022] 1 Experimental methods
[0023] Take 5 mg of the compound and dissolve it in deuterated methanol. Use 500 MHz NMR to obtain 1 HNMR, 13 C NMR, HSQC, HMBC, 1 H- 1 The H COSY and ROESY spectra were analyzed.
[0024] 2 Experimental results
[0025] As the instruction manual Figure 1 This is the structure of a spirostane alkaloid compound.
[0026] As the instruction manual Figure 3 As shown in (A), the HSQC spectrum shows δ c 11.01, δ c 19.79, δ c 13.90, δ c 17.68, δ c 17.99 is the methyl signal peak, corresponding to C-18, C-19, C-21, C-29, and C-Rha-6. c 38.54, δc 30.67, δ c 39.37, δ c 31.84, δ c 32.82, δ c 83.92, δ c 23.75, δ c 33.21, δ c 37.47, δ c 43.48, δ c 70.54, δ c 61.67, δ c 65.03 shows methylene carbon signals, corresponding to C-1, C-2, C-4, C-7, C-11, C-15, C-16, C-23, C-24, C-26, C-30, C-Gal-6, and C-Man-6. c 79.09, δ c 31.48, δ c 51.37, δ c 79.91, δ c 56.25, δ c 62.62, δ c 43.69, δ c 37.47, δ c 76.21, δ c 79.32, δ c 79.49, δ c 68.17, δ c 79.32, δ c 72.15, δ c 72.39, δ c 73.96, δ c 69.76, δ c 72.25, δ c 76.76, δ c 72.18, δ c 77.86 shows the methine signals, corresponding to C-3, C-8, C-9, C-12, C-14, C-17, C-20, C-25, C-28, C-Gal-1 to C-Gal-5, C-Rha-1 to C-Rha-5, and C-Man-1 to C-Man-5. c 38.12, δ c The carbon corresponding to 47.39 has no HSQC signal, which means it is a quaternary carbon, corresponding to C-10 and C-13 respectively.
[0027] As the instruction manual Figure 3As shown in (B), the HMBC spectrum shows that H-18 is correlated with C-12, C-13, C-14, and C-17, among which the chemical shift value of C-12 moves to the low field, indicating that it is connected to a heteroatom group. The absence of HSQC related signals at C-13 indicates that it is a quaternary carbon. C-17 is HMBC correlated with H-18 and H-21. H-19 is correlated with C-1, C-5, and C-9, among which C-1 has two HSQC correlations, which is a methylene group, C-9 has one HSQC signal, which is a methine group, and C-5 has no HSQC, and the chemical shift value is in the low field region, which is a quaternary carbon of olefinic carbon. H-21 is HMBC correlated with C-17, C-20, and C-22, among which C-22 is a characteristic carbon signal of spirostane alkaloids connected to nitrogen atoms, and C-20 and C-17 are both methine groups. Based on the correlation analysis of H-18 mentioned above, it can be assigned. H-28 has HMBC correlation with C27 and C-30, H-29 has HMBC correlation with C-28 and C-30, and the chemical shift values of C-28 and C-30 are located in the low field region, indicating that they are connected to highly electronegative groups. The correlation signals of the three sugar terminal carbons in the HMBC spectrum can determine the connection order of the trisaccharide. The correlation between H-Gal-1 and C-3, the correlation between H-Rha-1 and C-Gal-2, and the correlation between H-Man-1 and C-Gal-3 can determine the connection order of the trisaccharide.
[0028] As the instruction manual Figure 3 As shown in (B), H-Gal-1, H-Gal-2, H-Gal-3, H-Gal-4, and H-Gal-5 are correlated, H-Rha-1, H-Rha-2, H-Rha-3, and H-Rha-4 are correlated, H-Man-1, H-Man-2, and H-Man-3 are correlated, and H-Man-4, H-Man-5, and H-Man-6 are correlated. The specific classifications are shown in the following table. Table 1 1 HNMR(300MHZ)spectral dataforcompoundinCD3OD.
[0029] As the instruction manual Figure 4 As shown, the stereo configuration of the spirostane alkaloid substance is determined based on the ROESY signals of the hydrogen on the chiral carbon atom and other hydrogen atoms.
[0030] According to literature and SciFinder retrieval, the compound is a new compound, which is called Propanediolsolaoiate and its chemical name is (28S,30)-propanediol(3β,12β,22α,25R)-3.12-dihydroxy-siprosol-5-en-27-ate-3-O-beta-D-glucopyranosyl-(1-2)-[O-alpha-L-rhamnopyranosyl-(1-3)]-O-alpha-L-mannopyranosyl.
[0031] Example 3: Evaluation of the in vitro anti-inflammatory activity of a spirostane steroidal alkaloid
[0032] 1 Experimental methods
[0033] 1.1 Cell culture
[0034] Mouse mononuclear macrophage RAW264.7 cells were obtained from the cell bank of the Chinese Academy of Medical Sciences and cultured in a 37°C incubator containing 5% CO2 using DMEM medium containing 10% fetal bovine serum and 1% penicillin-streptomycin solution (100 U / mL).
[0035] 1.2 Evaluation of anti-inflammatory activity in vitro
[0036] (1) Experimental process:
[0037] Mouse mononuclear macrophage RAW264.7 cells were polarized by LPS (20 μg / mL) / IFN-γ (20 ng / mL) for 24 hours, and then the compound (50 μM) was added and incubated for 24 hours on a 6-well plate. The culture medium was removed, and the cells were washed 3 times with PBS. 1 mL of a 1:5000 diluted DCFH-DA probe solution was added to each well, and the cells were incubated at 37°C in the dark for 30 minutes. The supernatant was removed, and the cells were washed 3-5 times with serum-free medium. 1 mL of serum-free medium was added to each well, and the cells were immediately observed and photographed under a fluorescence microscope.
[0038] Mouse mononuclear macrophage RAW264.7 cells were polarized by LPS (20 μg / mL) and IFN-γ (20 ng / mL) for 24 hours, and then the compound (50 μM) was added to a 6-well plate for 24 hours. The culture supernatant was collected, 500 μL of trypsin was added to each well, incubated at 37°C for 2 minutes, 1 mL of complete culture medium was added, and the cells were collected. The cell culture medium was centrifuged at 3000g for 3 minutes at room temperature, the supernatant was removed, 50 μL of RRIPA lysis solution was added, and the cells were incubated on ice for 1 hour after ultrasonication for 5 minutes. The protein concentration was determined using a BCA kit to calibrate the cell number. The culture supernatant was centrifuged at 3000g for 10 minutes at room temperature, and the supernatant was taken for inflammatory factor ELISA kit detection, and the average inflammatory factor concentration was obtained by dividing by the number of cells.
[0039] (2) Experimental design:
[0040] ①Blank group: negative control group cells, without LPS / IFN-γ. ②Model group: positive control group cells, only with LPS / IFN-γ. ③Administration group: treated cells, with LPS / IFN-γ and compound (50μM).
[0041] 1.3 Statistical analysis
[0042] All experiments were performed independently for 3 times, and the experimental results were expressed as mean ± standard deviation (Mean ± SD). GraphPad Prism software was used for statistical analysis, and one-way analysis of variance was used for comparison between groups. P < 0.05 was considered statistically significant.
[0043] 2 Experimental results
[0044] The results of in vitro activity tests are as shown in the instructions. Figure 5 As shown in (A), the compound can significantly downregulate the content of reactive oxygen species (ROS) in polarized macrophages RAW264.7. Figure 5 (B) It can be seen that the compound can significantly downregulate the content of inflammatory factor IL-1β in polarized macrophages RAW264.7.
[0045] Example 3: Effect of a spirostane steroidal alkaloid on DSS-induced IBD model mice
[0046] 1 Experimental methods
[0047] 1.1 Establishment of mouse ulcerative colitis model
[0048] Mice were randomly divided into 3 groups, namely, blank group (Control), 3% dextran sulfate sodium salt model group (Model), and compound administration group (Treated), with 6 mice in each group. The blank group drank tap water for 7 days, and the other groups drank 3% DSS aqueous solution freely for 7 days (water was changed every other day). On the second day after the model was successfully established, gavage was started at a dose of 0.1 mL / 10 g of mouse body weight, among which the blank group and model group (normal saline gavage) and compound administration group (50 mg / kg compound gavage) were continuously gavaged for 7 days.
[0049] 1.2 Statistical analysis
[0050] All experiments were performed independently for 3 times, and the experimental results were expressed as mean ± standard deviation (Mean ± SD). GraphPad Prism software was used for statistical analysis, and one-way analysis of variance was used for comparison between groups. P < 0.05 was considered statistically significant.
[0051] 2 Experimental results
[0052] Attached to the instruction manual Figure 6 (A) It can be seen that compared with the blank group, the body weight of the model group decreased significantly, and the body weight of the model mice increased significantly after compound intervention; Figure 6 (B) It can be seen that compared with the model group, the survival rate of the model mice after compound intervention was significantly increased. Figure 7 (A) The results showed that the average colon length of the blank group was 5.87±0.32cm, the average colon length of the model group was 4.63±0.15cm, and the average colon length of the compound-administered group was 5.20±0.26cm. Compared with the control group, the colon length of the model group mice was significantly shortened (p<0.01), and the compound-administered group significantly improved the shortening of the colon length of the model mice (p<0.05). Figure 7 (B) The results showed that compared with the blank group, the spleen index of the mice in the model group was significantly increased (p < 0.001); compared with the model group, the spleen index of the mice in the compound administration group was significantly decreased (p < 0.005). Figure 8 The results showed that the colon mucosa of mice in the model group was destroyed, the crypt structure showed abnormal morphology such as twisted branches and even disappeared on a large scale, and epithelial goblet cells were lost on a large scale. Compared with the model group, the colon mucosa destruction, crypt disappearance, goblet cell abnormalities, inflammatory cell infiltration and other conditions of mice in the compound administration group were improved, and the histopathological score was significantly reduced (p < 0.005). Fig. 9 The results showed that the levels of IL-1β and TNF-α in the serum of mice in the model group were significantly increased (p < 0.001), and the compound administration intervention significantly downregulated the levels of proinflammatory factors IL-1β and TNF-α in the serum of model mice (p < 0.01).
Claims
1. Application of a compound in the preparation of an anti-enteritis product. The preparation method of the compound is as follows: fresh Solanum nigrum juice is used as a raw material, and the compound is separated and purified using an ODS-AQ-HG reverse phase column and a gel column.
2. The use according to claim 1, characterized in that: It is named (1S,2)-propanediol(3β,12β,22α,25R)-3,12-dihydroxy-siprosol-5-en-27-ate-12-O-beta-D-glucopyranosyl-(1-2)-[O-alpha-L-rhamnopyranosyl-(1-3)]-O-alpha-L-mannopyranosyl, abbreviated as propanediolsolaoiate. The structure is as follows 3. The use according to claim 1, characterized in that: The compound propanediol solaoiate has an inhibitory effect on the secretion of proinflammatory substances by polarized macrophages.
4. The use according to claim 1, characterized in that: The compound propanediol solaoiate can prevent and / or treat enteritis.
5. The use according to claim 1, characterized in that: Subjects of the compound propanediol solaoiate include humans, cats, dogs, pigs, horses or chickens.
6. The use according to claim 3, characterized in that: The macrophages were RAW264.7 cell line.
7. The use according to claim 3, characterized in that: Proinflammatory substances include ROS, IL-1β, etc.
8. A medicament comprising one or more compounds according to claim 2 or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
9. The use according to claims 2 and 8, wherein the drug is administered orally: tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets, effervescent tablets, sublingual tablets, capsules, hard capsules, soft capsules, microcapsules, microcapsules, microspheres, granules, pills, pellets, powders, oral liquids, suspensions, solutions, and sustained-release or controlled-release preparations.
10. The use according to claims 2 and 8, wherein the drug is administered by inhalation: aerosol and sustained-release or controlled-release preparations.
11. The use according to claims 2 and 8, wherein the drug is administered intravenously: injection, injection emulsion, lyophilized powder injection, and sustained-release or controlled-release preparation.
